loader
Please Wait
Applying Filters...

Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    List of Certificates of Suitability (CEPs) for r1_cep_2012_398___rev_02 Active Pharmaceutical Ingredient (API) issued by the EDQM. Original Data: EDQM Database

    Client Virtual Booth
    Menu

    Daiichi Sankyo

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 DAIICHI SANKYO CO., LTD. Tokyo JP (1)

    filter

    01 Olmesartan medoxomil (1)

    filter

    01 Japan (1)

    filter

    01 Valid (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us

    DAIICHI SANKYO CO., LTD. Tokyo JP

    Contact Supplier
    • FDA
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag Japan
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    Olmesartan medoxomil

    PDF Supplier PDF
    URL Supplier Web Content
    R1-CEP 2012-398 - Rev 02
    Valid
    Chemical
    2022-05-16
    2600
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for Certificates of Suitability (CEPs) for R1-CEP 2012-398 - Rev 02 of Daiichi Sankyo Co., Ltd. Tokyo Jp

    Looking for Certificates of Suitability (CEPs) for R1-CEP 2012-398 - Rev 02 of Daiichi Sankyo Co., Ltd. Tokyo Jp 1

    20

    Daiichi Sankyo Co., Ltd. Tokyo Jp, based in Japan, is a pharmaceutical company that stands out with its certifications from FDA.

    One of their significant offerings is Olmesartan medoxomil, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2012-398 - Rev 02

    This Chemical Type CEP, issued on May 16, 2022, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.

    Substance Number 2600 associated with this CEP further emphasizes

    Post Enquiry
    POST ENQUIRY